EN
TR
Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells
Öz
Background: Gadoteric acid is utilized in magnetic resonance imaging (MRI) as a paramagnetic macrocyclic gadolinium-based contrast agent (GBCA) in breast cancer patients. However, in parallel with its diagnostic and prognostic use, the effect of gadoteric acid on MCF-7 cells has not yet been demonstrated. The aim of this study was to examine the cytogenotoxic effects of gadoteric acid on MCF-7 breast cancer cells.
Methods: MCF-7 cells were incubated with gadoteric acid (0.1-100 mM). The cytotoxic effect was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The DNA damage effect of gadoteric acid on breast cancer cells by incubation at multiples of IC50 (1.84 mM, 3.67 mM, 7.35 mM, and 14.7 mM) was examined by Comet assay.
Results: Gadoteric acid (1-100 mM) significantly increased cytotoxicity in MCF-7 breast cancer cells (p < 0.001, p < 0.0001, and p < 0.0001, respectively). Gadoteric acid (1.84 mM, 3.67 mM, 7.35 mM, and 14.7 mM) dramatically increased genotoxicity in breast cancer cells (p < 0.01, p < 0.01, p < 0.01 and p < 0.01, respectively).
Conclusion: The results of our study indicate that gadoteric acid, which is used for diagnostic purposes in breast cancer, shows cytogenotoxic effect in MCF-7 cells under in vitro conditions. Our findings constitute the basic stepping stone for further studies in terms of therapeutic potential and additional studies are needed for clinical relevance.
Anahtar Kelimeler
Etik Beyan
We performed in vitro experiments with the commercially available MCF-7 breast cancer cell line. Since primary tissue samples, human participants and/or animal subjects were not used in our research process, ethical approval from any ethics committee is not required. MCF-7 cells were sourced from the American Type Culture Collection (ATCC, Shanghai, China).
Kaynakça
- 1.Trayes KP, Cokenakes SEH. Breast CancerTreatment. Am Fam Physician. 2021;104:171-8.
- 2.Burguin A, Diorio C, Durocher F. Breast cancertreatments: updates and new challenges. Journal ofpersonalized medicine 2021;11:808.
- 3.Morelli MB, Bongiovanni C, Da Pra S, et al.Cardiotoxicity of anticancer drugs: molecularmechanisms and strategies for cardioprotection.Frontiers in cardiovascular medicine2022;9:847012.
- 4.Fernández Y, Cueva J, Palomo AG, et al. Noveltherapeutic approaches to the treatment ofmetastatic breast cancer. Cancer Treat Rev.2010;36:33-42.
- 5.Zhang W, Wang M, Lv W, et al. Long-TermTreatment with Gadopentetic Acid or GadodiamideIncreases TRPC5 Expression and DecreasesAdriamycin Nuclear Accumulation in Breast CancerCells. Cells. 2023;12.
- 6.Seithe T, Braun J, Wolf M, et al. Diagnostic efficacyand safety of gadoteric acid MR mammography in1537 patients. Eur J Radiol. 2016;85:2281-7.
- 7.Coimbra S, Rocha S, Sousa NR, et al. ToxicityMechanisms of Gadolinium and Gadolinium-BasedContrast Agents-A Review. Int J Mol Sci. 2024;25.
- 8.Cowling T, Frey N. Macrocyclic and lineargadolinium based contrast agents for adultsundergoing magnetic resonance imaging: a reviewof safety. 2019.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi, Tıp Eğitimi, Sağlık Hizmetleri ve Sistemleri (Diğer)
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
16 Eylül 2025
Gönderilme Tarihi
11 Temmuz 2025
Kabul Tarihi
4 Eylül 2025
Yayımlandığı Sayı
Yıl 2025 Cilt: 52 Sayı: 3
APA
Bilgin, B., & Kenger, I. H. (2025). Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells. Dicle Medical Journal, 52(3), 559-567. https://doi.org/10.5798/dicletip.1785119
AMA
1.Bilgin B, Kenger IH. Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells. diclemedj. 2025;52(3):559-567. doi:10.5798/dicletip.1785119
Chicago
Bilgin, Batuhan, ve Ibrahim Halil Kenger. 2025. “Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells”. Dicle Medical Journal 52 (3): 559-67. https://doi.org/10.5798/dicletip.1785119.
EndNote
Bilgin B, Kenger IH (01 Eylül 2025) Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells. Dicle Medical Journal 52 3 559–567.
IEEE
[1]B. Bilgin ve I. H. Kenger, “Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells”, diclemedj, c. 52, sy 3, ss. 559–567, Eyl. 2025, doi: 10.5798/dicletip.1785119.
ISNAD
Bilgin, Batuhan - Kenger, Ibrahim Halil. “Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells”. Dicle Medical Journal 52/3 (01 Eylül 2025): 559-567. https://doi.org/10.5798/dicletip.1785119.
JAMA
1.Bilgin B, Kenger IH. Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells. diclemedj. 2025;52:559–567.
MLA
Bilgin, Batuhan, ve Ibrahim Halil Kenger. “Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells”. Dicle Medical Journal, c. 52, sy 3, Eylül 2025, ss. 559-67, doi:10.5798/dicletip.1785119.
Vancouver
1.Batuhan Bilgin, Ibrahim Halil Kenger. Cytotoxicity and Genotoxicity Assessment of Gadoteric Acid in Breast Cancer Cells. diclemedj. 01 Eylül 2025;52(3):559-67. doi:10.5798/dicletip.1785119